Electronic devices have been systematically provided to participants to report Patient Reported Outcome (PRO) data in clinical trials and electronic Patient Reported Outcomes (ePRO) data collection methods have evolved over time. The current desire to reduce participant burden and drug development costs, combined with improved technology, has led to increasing interest in having study participants use their own devices (‘bring your own device’ or BYOD) to collect PRO data.

However, the uptake of BYOD technologies remains low despite significant interest from industry in their development. The lack of clear regulatory guidance on BYOD approaches has created a vicious circle: clinical teams are not encouraged to pioneer clinical trials submissions using BYOD-collected data, which limits publications on BYOD success stories, meaning that cautious clinical trial teams are not prompted to take the plunge and broadly adopt BYOD options.

What does the industry need to make a step forward and implement BYOD strategies? How can confidence grow so that study participants can benefit from the comfort of using their own device to collect PRO data? This white paper sets explicit expectations as to what BYOD strategies bring as well as the associated risk, and proposes structured help to support successful BYOD strategy decision-making processes and implementation.

CONTENT

Draw clear expectations: What are the true benefits of Implementing a BYOD strategy?

Compliance

Flexibility

Understanding the challenges of BYOD: What do we need to pay attention to?

Data storage constraints

- Data security challenges

Smartphone availability verifications

Choose a relevant BYOD strategy: When does it make sense?

Study design criteria

Patient population criteria

Geographical constraints

READ THE FULL WHITE PAPER:



Download the white paper

Key Words:

- BYOD
- ePRO
- clinical trials
- data collection

Learn more:



ePRO data collection: Decision-Making for the Adoption of a Bring Your Own Device Strategy

17 May 2023

Electronic devices have been systematically provided to participants to report Patient Reported Outcome (PRO) data

Read More »

Working With Patient Associations: What Is The Key To A Positive Interaction?

2 May 2023

What rare disease patients and families want is a simpler life. Discover here what makes

Read More »

How A Patient Association Gave Rise To A Company

25 April 2023

A patient association in rare diseases is first and foremost families who all have one

Read More »

Direct Insights from Cancer Patients: How they help us understand disease burden and the need for an individualized approach

12 April 2023

Cultural differences and individual preferences have a significant impact on healthcare and clinical trial experience.

Read More »



Kayentis and ClinOne combined solution

4 April 2023

Improve your eCOA data collection and clinical trial efficiency thanks to Kayentis and ClinOne combined

Read More »

Rare Disease Case Study

30 March 2023

Over 90% of rare diseases have no treatment… There are more than 6,000 known rare diseases…

Read More »